Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WB001
- Development stage
- Preclinical
- Lead developer
- Weben Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WB001 is an oral small-molecule compound developed by Weben Pharma for the treatment of pancreatic, lung, and stomach cancers. Currently in preclinical development, WB001 is the lead candidate in the company's oncology pipeline. It has demonstrated significant anti-tumor efficacy in human cancer cell line xenograft models in nude mice. Although its specific molecular target and mechanism of action have not been publicly disclosed, its oral bioavailability and broad-spectrum activity in solid tumor models mark it as a primary focus for Weben Pharma's therapeutic development.
- Brand names
- WB001WB-001WB 001
- Other names
- WoebotWoebot for Postpartum Depression
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on WB001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WB001.